An innovative and convenient test method that detects early breast cancer with an accuracy
of 92% (based on the patent) by using only a very small amount of blood.
Bertis has developed multiple markers that can detect early breast cancer with an accuracy of 92% through identification of multiple proteins that
are expressed sensitively in early-stage breast cancer and combination of certain proteins that demonstrated high accuracy
and reproducibility among these combinations.
MASTOCHECK was developed by a team led by Professor Dong-Young Noh, a world-renowned authority on breast cancer, of Seoul National University.
After analyzing approximately 600,000 proteins and selecting 3 markers exhibiting optimal accuracy,
the highest accuracy was obtained by adding Bertis’ own algorithm that enhances accuracy.
After several years of repeated validation work, a medical device product license was obtained from the MFDS in January 2019. To date (as of September 2023), MASTOCHECK has been introduced to about 400 hospitals and screening institutions nationwide, with priority given to large screening institutions.
ADDITIONAL INFORMATION AND DATA ON MASTOCHECK